These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 315711)
1. Effects of the converting enzyme inhibitor (SQ 20881) on the pulmonary circulation in man. Niarchos AP; Roberts AJ; Laragh JH Am J Med; 1979 Nov; 67(5):785-91. PubMed ID: 315711 [TBL] [Abstract][Full Text] [Related]
2. Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Curtiss C; Cohn JN; Vrobel T; Franciosa JA Circulation; 1978 Nov; 58(5):763-70. PubMed ID: 699245 [TBL] [Abstract][Full Text] [Related]
3. Hemodynamic effects of the converting enzyme inhibitor teprotide in normal- and high-renin hypertension. Niarchos AP; Pickering TG; Wallace JM; Case DB; Laragh JH Clin Pharmacol Ther; 1980 Nov; 28(5):592-601. PubMed ID: 6160013 [TBL] [Abstract][Full Text] [Related]
4. The effect of angiotensin converting enzyme inhibition of coronary blood flow and hemodynamics in patients without coronary artery disease. Faxon DP; Creager MA; Halperin JL; Sussman HA; Gavras H; Ryan TJ Int J Cardiol; 1982; 2(2):251-62. PubMed ID: 6185446 [TBL] [Abstract][Full Text] [Related]
5. Systemic and pulmonary hemodynamic effects of saralasin infusion in hypertension. Predictability of plasma renin status from hemodynamic changes. Mookherjee S; Obeid A; Warner R; Anderson G; Eich R; Smulyan H Am J Cardiol; 1978 Dec; 42(6):987-92. PubMed ID: 727149 [TBL] [Abstract][Full Text] [Related]
6. Redistribution of regional blood flow following angiotensin-converting enzyme inhibition. Comparison of normal subjects and patients with heart failure. Faxon DP; Creager MA; Halperin JL; Bernard DB; Ryan TJ Am J Med; 1984 May; 76(5B):104-10. PubMed ID: 6203405 [TBL] [Abstract][Full Text] [Related]
7. Estimating renin participation in hypertension: superiority of converting enzyme inhibitor over saralasin. Case DB; Wallace JM; Keim HJ; Weber MA; Drayer JI; White RP; Sealey JE; Laragh JH Am J Med; 1976 Nov; 61(5):790-6. PubMed ID: 185903 [TBL] [Abstract][Full Text] [Related]
8. Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. Halperin JL; Faxon DP; Creager MA; Bass TA; Melidossian CD; Gavras H; Ryan TJ Am J Cardiol; 1982 Nov; 50(5):967-72. PubMed ID: 6182786 [TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and clinical significance of the pulmonary vascular response to long-term captopril therapy in patients with severe chronic heart failure. Packer M; Lee WH; Medina N; Yushak M J Am Coll Cardiol; 1985 Sep; 6(3):635-45. PubMed ID: 2993397 [TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics. Liang CS; Gavras H; Hood WB J Clin Invest; 1978 Apr; 61(4):874-83. PubMed ID: 659580 [TBL] [Abstract][Full Text] [Related]
11. Role of the renin-angiotensin system in blood pressure regulation. The cardiovascular effects of converting enzyme inhibition in normotensive subjects. Niarchos AP; Pickering TG; Case DB; Sullivan P; Laragh JH Circ Res; 1979 Dec; 45(6):829-37. PubMed ID: 498446 [No Abstract] [Full Text] [Related]
13. Left ventricular performance and pulmonary circulation following addition of nitrous oxide to morphine during coronary-artery surgery. Lappas DG; Buckley MJ; Laver MB; Daggett WM; Lowenstein E Anesthesiology; 1975 Jul; 43(1):61-9. PubMed ID: 1147309 [TBL] [Abstract][Full Text] [Related]
14. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. Case DB; Wallace JM; Keim HJ; Weber MA; Sealey JE; Laragh JH N Engl J Med; 1977 Mar; 296(12):641-6. PubMed ID: 190537 [TBL] [Abstract][Full Text] [Related]
15. Accentuated vascular and endocrine response to SQ 20881 in hypertension. Williams GH; Hollenberg NK N Engl J Med; 1977 Jul; 297(4):184-8. PubMed ID: 195203 [TBL] [Abstract][Full Text] [Related]
16. Nitrous oxide does not exacerbate pulmonary hypertension or ventricular dysfunction in patients with mitral valvular disease. Konstadt SN; Reich DL; Thys DM Can J Anaesth; 1990 Sep; 37(6):613-7. PubMed ID: 2208532 [TBL] [Abstract][Full Text] [Related]
17. Increased glomerular filtration rate after converting-enzyme inhibition in essential hypertension. Hollenberg NK; Swartz SL; Passan DR; Williams GH N Engl J Med; 1979 Jul; 301(1):9-12. PubMed ID: 221809 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin converting enzyme inhibition has no effect on blood pressure and splanchnic perfusion after cardiac surgery. Parviainen I; Rantala A; Ruokonen E; Tenhunen J; Takala J J Crit Care; 1998 Jun; 13(2):73-80. PubMed ID: 9627274 [TBL] [Abstract][Full Text] [Related]
19. Cardiovascular responses to isometric exercise and standing in normotensive subjects during converting enzyme inhibition with teprotide. Niarchos AP; Pickering TG; Laragh JH Hypertension; 1982; 4(4):538-44. PubMed ID: 6185419 [TBL] [Abstract][Full Text] [Related]
20. A new experimental model for measurement of pulmonary arterial haemodynamic variables in conscious rats before and after pulmonary embolism and during general anaesthesia. Riegger GA; Hoferer P Cardiovasc Res; 1990 Apr; 24(4):340-4. PubMed ID: 2346968 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]